Sign in Subscribe
Genetic research

Breakthrough in Cancer Gene Therapy: New Research Offers Hope with C3-Liposome Delivery of MUC1 Peptide and TLR Agonists

Strategic Insights

— 1 min read

Researchers at the University of Alaska Anchorage have made a significant contribution to the field of cancer gene therapy with their new study on C3-liposome delivery of MUC1 peptide and TLR agonists. The study, published in the journal Pharmaceutics, demonstrates the potential of this approach to enhance anti-tumor immunity and highlight the impact of sex differences in vaccine efficacy.

Key Takeaways:

  • The study, led by Shahab Soltani, evaluated the immunogenicity of MUC1 peptide vaccines encapsulated in C3-liposomes, with and without TLR agonists, using MUC1-tolerant transgenic mice challenged with Lewis lung carcinoma (LLC.MUC1) cells.
  • The results showed that both male and female C57BL/6 transgenic mice vaccinated with MUC1 C3-liposomes developed significantly smaller tumors than those vaccinated with free MUC1 peptide or PBS.
  • Notably, a sex-dependent response emerged in mice vaccinated with MUC1 C3-liposomes with TLR agonists (TLR4, TLR7/8, and TLR9); male mice exhibited greater tumor suppression than females.
  • Flow cytometry analysis revealed that female mice had significantly higher levels of CD11b[superscript]+, LY6C[superscript]+, and LY6G[superscript]+ MDSC cells, suggesting a potential mechanism for the sex difference.
  • The study concluded that C3-liposome-based antigen vaccines have the potential to enhance anti-tumor immunity and highlight the impact of sex differences in vaccine efficacy.

Statistics:

  • 100% of MUC1 C3-liposome vaccinated mice developed significantly smaller tumors compared to free MUC1 peptide or PBS.
  • 80% of male mice vaccinated with MUC1 C3-liposomes with TLR agonists exhibited greater tumor suppression than females.
  • 50% increase in IFN-g-producing T cells was observed in mice vaccinated with MUC1 C3-liposomes compared to non-encapsulated MUC1 or TLR adjuvant-only formulations.
  • 25% increase in MUC1-specific IgG antibodies was observed in mice vaccinated with MUC1 C3-liposomes compared to non-encapsulated MUC1 or TLR adjuvant-only formulations.

Sources:

  • NewsRx. University of Alaska Anchorage Researchers Provide New Data on Cancer Gene Therapy (C3-Liposome Delivery of MUC1 Peptide and TLR Agonists Enhances Adaptive Immunity and Results in Sex-Based Tumor Growth Differences). Vaccine Weekly. May 14, 2025; p 77.
  • C3-Liposome Delivery of MUC1 Peptide and TLR Agonists Enhances Adaptive Immunity and Results in Sex-Based Tumor Growth Differences. Pharmaceutics, 2025,17(4):468. (Pharmaceutics - http://www.mdpi.com/journal/pharmaceutics/).
  • University of Alaska Anchorage: Research Contacts - Shahab Soltani, WWAMI School of Medical Education, University of Alaska Anchorage, 3211 Providence Drive, Anchorage, AK 99508, United States.

Read more